Literature DB >> 16052549

Aggregation kinetics of recombinant human FVIII (rFVIII).

Karthik Ramani1, Vivek Purohit, C Russell Middaugh, Sathyamangalam V Balasubramanian.   

Abstract

The physical phenomenon of aggregation can have profound impact on the stability of therapeutic proteins. This study focuses on the aggregation behavior of recombinant human FVIII (rFVIII), a multi-domain protein used as the first line of therapy for hemophilia A, a bleeding disorder caused by the deficiency or dysfunction of factor VIII (FVIII). Thermal denaturation of rFVIII was investigated using circular dichroism (CD) spectroscopy and size exclusion chromatography (SEC). The dependence of unfolding on heating rate indicated that the thermal denaturation of the protein was at least partly under kinetic control. The data was interpreted in terms of a simple two-state kinetic model, N(Native) k --> A(Aggregated), where k is a first-order kinetic constant that changes with temperature, as given by the Arrhenius equation. Analysis of the data in terms of the above scheme suggested that under the experimental conditions used in this study, the rate-controlling step in the aggregation of rFVIII may be a unimolecular reaction involving conformational changes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052549      PMCID: PMC2574007          DOI: 10.1002/jps.20432

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

1.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein.

Authors:  A W Vermeer; W Norde
Journal:  Biophys J       Date:  2000-01       Impact factor: 4.033

Review 2.  Bioequivalence and the immunogenicity of biopharmaceuticals.

Authors:  Huub Schellekens
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

3.  Unfolding and aggregation during the thermal denaturation of streptokinase.

Authors:  Ana I Azuaga; Christopher M Dobson; Pedro L Mateo; Francisco Conejero-Lara
Journal:  Eur J Biochem       Date:  2002-08

Review 4.  Protein aggregation: folding aggregates, inclusion bodies and amyloid.

Authors:  A L Fink
Journal:  Fold Des       Date:  1998

5.  Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition.

Authors:  Sampathkumar Krishnan; Eva Y Chi; Jonathan N Webb; Byeong S Chang; Daxian Shan; Merrill Goldenberg; Mark C Manning; Theodore W Randolph; John F Carpenter
Journal:  Biochemistry       Date:  2002-05-21       Impact factor: 3.162

6.  Conformational origin of the aggregation of recombinant human factor VIII.

Authors:  A O Grillo; K L Edwards; R S Kashi; K M Shipley; L Hu; M J Besman; C R Middaugh
Journal:  Biochemistry       Date:  2001-01-16       Impact factor: 3.162

7.  Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.

Authors:  A Braun; L Kwee; M A Labow; J Alsenz
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

8.  Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).

Authors:  Karthik Ramani; Vivek S Purohit; Razvan D Miclea; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

9.  Aggregation of recombinant human interferon gamma: kinetics and structural transitions.

Authors:  B S Kendrick; J L Cleland; X Lam; T Nguyen; T W Randolph; M C Manning; J F Carpenter
Journal:  J Pharm Sci       Date:  1998-09       Impact factor: 3.534

10.  A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma.

Authors:  B S Kendrick; J F Carpenter; J L Cleland; T W Randolph
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more
  7 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

3.  Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.

Authors:  Dipak S Pisal; Matthew P Kosloski; C Russell Middaugh; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2012-03-02       Impact factor: 3.534

4.  Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Authors:  Aaron Peng; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

5.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

6.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

7.  Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.

Authors:  Gauri Rao; Vandana Iyer; Matthew P Kosloski; Dipak S Pisal; Eunkyoung Shin; C Russell Middaugh; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.